Revolution Medicines, Inc. Operating Lease, Right-of-Use Asset, Amortization Expense
Revolution Medicines, Inc. (RVMD) reported Operating Lease, Right-of-Use Asset, Amortization Expense of $4.24 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Cash Flow › Operating Activities
us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense · last filed 2026-08-05
- Revolution Medicines, Inc. operating lease, right-of-use asset, amortization expense for the quarter ending 2026-06-30 was $2.05M, a 15.42% increase year-over-year.
- Revolution Medicines, Inc. operating lease, right-of-use asset, amortization expense for the quarter ending 2026-03-31 was $2.19M, a 24.59% increase year-over-year.
- Revolution Medicines, Inc. operating lease, right-of-use asset, amortization expense for the quarter ending 2025-12-31 was $2.37M, a 70.83% increase year-over-year.
- Revolution Medicines, Inc. operating lease, right-of-use asset, amortization expense for the quarter ending 2025-09-30 was $2.01M, a 107.65% increase year-over-year.
- Revolution Medicines, Inc. operating lease, right-of-use asset, amortization expense for fiscal 2025 was $7.91M, a 88.47% increase from fiscal 2024.
- Revolution Medicines, Inc. operating lease, right-of-use asset, amortization expense for fiscal 2024 was $4.20M, a 31.17% increase from fiscal 2023.
- Revolution Medicines, Inc. operating lease, right-of-use asset, amortization expense for fiscal 2023 was $3.20M, a 30.68% decline from fiscal 2022.
- Revolution Medicines, Inc. operating lease, right-of-use asset, amortization expense for fiscal 2022 was $4.62M, a 45.13% increase from fiscal 2021.
| Period end | Operating Lease, Right-of-Use Asset, Amortization Expense 3 month | Operating Lease, Right-of-Use Asset, Amortization Expense 6 month | Operating Lease, Right-of-Use Asset, Amortization Expense 9 month | Operating Lease, Right-of-Use Asset, Amortization Expense 12 month |
|---|---|---|---|---|
| 2026-06-30 | $2.05M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05 | $4.24M 10-Q · filed 2026-08-05 | $6.61M derived: sum of 3 quarters · filed 2026-08-05 | $8.61M derived: sum of 4 quarters · filed 2026-08-05 |
| 2026-03-31 | $2.19M 10-Q · filed 2026-05-06 | $4.55M derived: sum of 2 quarters · filed 2026-05-06 | $6.56M derived: sum of 3 quarters · filed 2026-05-06 | $8.34M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-12-31 | $2.37M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-25 | $4.37M derived: sum of 2 quarters · filed 2026-02-25 | $6.15M derived: sum of 3 quarters · filed 2026-08-05 | $7.91M 10-K · filed 2026-02-25 |
| 2025-09-30 | $2.01M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05 | $3.79M derived: sum of 2 quarters · filed 2026-08-05 | $5.54M 10-Q · filed 2025-11-05 | $6.93M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-06-30 | $1.78M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05 | $3.53M 10-Q · filed 2026-08-05 | $4.92M derived: sum of 3 quarters · filed 2026-08-05 | $5.89M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-03-31 | $1.76M 10-Q · filed 2026-05-06 | $3.14M derived: sum of 2 quarters · filed 2026-05-06 | $4.11M derived: sum of 3 quarters · filed 2026-05-06 | $5.00M derived: sum of 4 quarters · filed 2026-05-06 |
| 2024-12-31 | $1.39M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-25 | $2.35M derived: sum of 2 quarters · filed 2026-02-25 | $3.24M derived: sum of 3 quarters · filed 2026-02-25 | $4.20M 10-K · filed 2026-02-25 |
| 2024-09-30 | $967.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05 | $1.85M derived: sum of 2 quarters · filed 2025-11-05 | $2.81M 10-Q · filed 2025-11-05 | $4.05M derived: sum of 4 quarters · filed 2026-02-25 |
| 2024-06-30 | $888.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-06 | $1.84M 10-Q · filed 2025-08-06 | $3.09M derived: sum of 3 quarters · filed 2026-02-25 | $3.70M derived: sum of 4 quarters · filed 2026-02-25 |
| 2024-03-31 | $956.00K 10-Q · filed 2025-05-07 | $2.20M derived: sum of 2 quarters · filed 2026-02-25 | $2.81M derived: sum of 3 quarters · filed 2026-02-25 | $3.09M derived: sum of 4 quarters · filed 2026-02-25 |
| 2023-12-31 | $1.24M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-25 | $1.85M derived: sum of 2 quarters · filed 2026-02-25 | $2.14M derived: sum of 3 quarters · filed 2026-02-25 | $3.20M 10-K · filed 2026-02-25 |
| 2023-09-30 | $611.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-06 | $894.00K derived: sum of 2 quarters · filed 2024-11-06 | $1.96M 10-Q · filed 2024-11-06 | $3.14M derived: sum of 4 quarters · filed 2025-02-26 |
| 2023-06-30 | $283.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-07 | $1.34M 10-Q · filed 2024-08-07 | $2.53M derived: sum of 3 quarters · filed 2025-02-26 | $3.70M derived: sum of 4 quarters · filed 2025-02-26 |
| 2023-03-31 | $1.06M 10-Q · filed 2024-05-08 | $2.24M derived: sum of 2 quarters · filed 2025-02-26 | $3.42M derived: sum of 3 quarters · filed 2025-02-26 | $4.55M derived: sum of 4 quarters · filed 2025-02-26 |
| 2022-12-31 | $1.18M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-26 | $2.36M derived: sum of 2 quarters · filed 2025-02-26 | $3.49M derived: sum of 3 quarters · filed 2025-02-26 | $4.62M 10-K · filed 2025-02-26 |
| 2022-09-30 | $1.18M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-06 | $2.31M derived: sum of 2 quarters · filed 2023-11-06 | $3.43M 10-Q · filed 2023-11-06 | $4.41M derived: sum of 4 quarters · filed 2024-02-26 |
| 2022-06-30 | $1.14M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-08 | $2.26M 10-Q · filed 2023-08-08 | $3.24M derived: sum of 3 quarters · filed 2024-02-26 | $3.93M derived: sum of 4 quarters · filed 2024-02-26 |
| 2022-03-31 | $1.12M 10-Q · filed 2023-05-08 | $2.10M derived: sum of 2 quarters · filed 2024-02-26 | $2.79M derived: sum of 3 quarters · filed 2024-02-26 | $3.56M derived: sum of 4 quarters · filed 2024-02-26 |
| 2021-12-31 | $979.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-26 | $1.67M derived: sum of 2 quarters · filed 2024-02-26 | $2.44M derived: sum of 3 quarters · filed 2024-02-26 | $3.18M 10-K · filed 2024-02-26 |
| 2021-09-30 | $691.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-07 | $1.46M derived: sum of 2 quarters · filed 2022-11-07 | $2.20M 10-Q · filed 2022-11-07 | |
| 2021-06-30 | $770.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-09 | $1.51M 10-Q · filed 2022-08-09 | ||
| 2021-03-31 | $740.00K 10-Q · filed 2022-05-09 | |||
| 2020-12-31 | $2.87M 10-K · filed 2023-02-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| BIOGEN INC. (BIIB) | United States | $33.427B | 19.60 |
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |